An interventional study of ELECTROCARDIOGRAM (ECG) PATCH WEAR in Atrial Fibrillation, sponsored by Apple Inc.. Completed at 4 sites in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-24.
Sponsored by Apple Inc. · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 122nd largest by enrollment of the 679 interventional ones that give a count, is one of 57 that started in 2020, is one of 405 with no phase, and was the 698th registered.
4,016 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 40+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 22 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 57 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 573 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
Apple Inc. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Apple Inc. has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
75 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 75 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the performances of investigational Irregular Rhythm Notification Feature (version 2.0) and Atrial Fibrillation History Feature algorithms.
The purpose of the study is to evaluate the performances of investigational Irregular Rhythm Notification Feature (version 2.0) and Atrial Fibrillation History Feature algorithms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Cohort 2, have no known medical history of AF and active diagnosis of at least one of the following arrhythmias within the past 2 years:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This will include subjects with no known history of AF
Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR
This will include subjects with no known history of aF, but with history of frequent premature atrial contractions (PACs), frequent premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), or non-sustained ventricular tachycardia (NSVT)
Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR
This will include subjects with known history of paroxysmal, persistent, or chronic AF
Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR
Will include subjects with permanent AF
Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR
ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
Also known as: CARDEASOLO
SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]
Sensitivity of the irregular rhythm notification for the identification of persons with AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Sensitivity is defined as the percentage of subjects exhibiting AF on the ambulatory ECG who also received an irregular rhythm notification concordant with at least one episode of AF.
Time frame: 13 DAYS
SPECIFICITY OF LACK OF IRREGULAR RHYTHM NOTIFICATIONS FEATURE [IRNF]
Specificity of the lack of irregular rhythm notification for the identification of persons without AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Specificity is defined as the percentage of subjects not exhibiting AF on the ambulatory ECG who also did not receive any irregular rhythm notifications.
Time frame: 13 DAYS
WEEKLY ATRIAL FIBRILLATION BURDEN FEATURE ESTIMATE [AFBF]
Weekly AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during wrist device wear over the prior 7 consecutive days. The weekly AF burden was estimated by both the reference device and the algorithm and reported using the Bland-Altman limits of Agreement.
Time frame: 13 DAYS
POSITIVE PREDICTIVE VALUE OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]
Notification-level positive predictive value (PPV) with AF by ambulatory ECG at the time of any tachogram comprising the notification.
Time frame: 13 DAYS
TACHOGRAM ALERT SENSITIVITY [IRNF]
Tachogram-level sensitivity performance for tachograms comprising alerts.
Time frame: 13 DAYS
TACHOGRAM ALERT SPECIFICITY [IRNF]
Tachogram-level specificity performance for tachograms comprising alerts.
Time frame: 13 DAYS
Tachogram Alert False Positive Rate [IRNF]
Tachogram-level False Positive rate performance for tachograms comprising alerts.
Time frame: 13 DAYS
Tachogram Alert Positive Predictive Value [IRNF]
Tachogram-level Positive Predictive value performance for tachograms comprising alerts.
Time frame: 13 DAYS
Tachogram Alert Negative Predictive Value [IRNF]
Tachogram-level Negative Predictive value performance for tachograms comprising alerts.
Time frame: 13 DAYS
TACHOGRAM SENSITIVITY [IRNF]
Tachogram-level sensitivity performance for all generated tachograms.
Time frame: 13 DAYS
TACHOGRAM SPECIFICITY [IRNF]
Tachogram-level specificity performance for all generated tachograms.
Time frame: 13 DAYS
TACHOGRAM FALSE POSITIVE RATE [IRNF]
Tachogram-level false positive rate performance for all generated tachograms.
Time frame: 13 DAYS
TACHOGRAM POSITIVE PREDICTIVE VALUE [IRNF]
Tachogram-level positive predictive value performance for all generated tachograms.
Time frame: 13 DAYS
TACHOGRAM NEGATIVE PREDICTIVE VALUE [IRNF]
Tachogram-level negative predictive value performance for all generated tachograms.
Time frame: 13 DAYS
TACHOGRAM SENSITIVITY [AFBF]
Sensitivity of tachograms for the identification of AF by ambulatory ECG.
Time frame: 13 days
TACHOGRAM SPECIFICITY [AFBF]
Specificity of tachograms for the identification of AF by ambulatory ECG.
Time frame: 13 days
TACHOGRAM POSITIVE PREDICTIVE VALUE [AFBF]
Positive Predictive Value of tachograms for the identification of AF by ambulatory ECG.
Time frame: 13 days
TACHOGRAM NEGATIVE PREDICTIVE VALUE [AFBF]
Negative Predictive Value of tachograms for the identification of AF by ambulatory ECG.
Time frame: 13 days
DAY-SPECIFIC AF BURDEN ESTIMATE [AFBF]
Day-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific day of the week.
Time frame: 13 DAYS
FOUR-HOUR SEGMENT SPECIFIC AF BURDEN ESTIMATE [AFBF]
Four-hour segment-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific four-hour segment of a day
Time frame: 13 DAYS
| Milestone | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 |
|---|---|---|---|---|
| Started | 78 | 82 | 366 | 47 |
| Completed | 70 | 64 | 304 | 45 |
| Not completed | 8 | 18 | 62 | 2 |
Sensitivity of the irregular rhythm notification for the identification of persons with AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Sensitivity is defined as the percentage of subjects exhibiting AF on the ambulatory ECG who also received an irregular rhythm notification concordant with at least one episode of AF.
| percentage of participants | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF] | NA | — | NA | NA | 88.6 |
Specificity of the lack of irregular rhythm notification for the identification of persons without AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Specificity is defined as the percentage of subjects not exhibiting AF on the ambulatory ECG who also did not receive any irregular rhythm notifications.
| percentage of participants | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| SPECIFICITY OF LACK OF IRREGULAR RHYTHM NOTIFICATIONS FEATURE [IRNF] | NA | — | NA | NA | 99.3 |
Weekly AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during wrist device wear over the prior 7 consecutive days. The weekly AF burden was estimated by both the reference device and the algorithm and reported using the Bland-Altman limits of Agreement.
| Bland-Altman Limits of Agreement | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|
| Lower Limit of Agreement (%) | NA | NA | -11.4 |
| Upper Limit of Agreement (%) | NA | NA | 12.8 |
Notification-level positive predictive value (PPV) with AF by ambulatory ECG at the time of any tachogram comprising the notification.
| percentage of notifications | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| POSITIVE PREDICTIVE VALUE OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF] | — | — | NA | NA | 100 |
Tachogram-level sensitivity performance for tachograms comprising alerts.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| TACHOGRAM ALERT SENSITIVITY [IRNF] | — | — | NA | NA | 95.05 |
Tachogram-level specificity performance for tachograms comprising alerts.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| TACHOGRAM ALERT SPECIFICITY [IRNF] | — | — | NA | NA | 0 |
Tachogram-level False Positive rate performance for tachograms comprising alerts.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| Tachogram Alert False Positive Rate [IRNF] | — | — | NA | NA | 100 |
Tachogram-level Positive Predictive value performance for tachograms comprising alerts.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| Tachogram Alert Positive Predictive Value [IRNF] | — | — | NA | NA | 99.83 |
Tachogram-level Negative Predictive value performance for tachograms comprising alerts.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| Tachogram Alert Negative Predictive Value [IRNF] | — | — | NA | NA | 0 |
Tachogram-level sensitivity performance for all generated tachograms.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| TACHOGRAM SENSITIVITY [IRNF] | NA | — | NA | NA | 85.5 |
Tachogram-level specificity performance for all generated tachograms.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| TACHOGRAM SPECIFICITY [IRNF] | NA | — | NA | NA | 99.9 |
Tachogram-level false positive rate performance for all generated tachograms.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| TACHOGRAM FALSE POSITIVE RATE [IRNF] | NA | 0.05 | NA | NA | 0.22 |
Tachogram-level positive predictive value performance for all generated tachograms.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| TACHOGRAM POSITIVE PREDICTIVE VALUE [IRNF] | — | — | NA | NA | 99.8 |
Tachogram-level negative predictive value performance for all generated tachograms.
| percentage of tachograms | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|---|---|
| TACHOGRAM NEGATIVE PREDICTIVE VALUE [IRNF] | NA | — | NA | NA | 77.9 |
Sensitivity of tachograms for the identification of AF by ambulatory ECG.
| percentage of tachograms | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|
| TACHOGRAM SENSITIVITY [AFBF] | NA | NA | 92.6 |
Specificity of tachograms for the identification of AF by ambulatory ECG.
| percentage of tachograms | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|
| TACHOGRAM SPECIFICITY [AFBF] | NA | NA | 98.8 |
Positive Predictive Value of tachograms for the identification of AF by ambulatory ECG.
| percentage of tachograms | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|
| TACHOGRAM POSITIVE PREDICTIVE VALUE [AFBF] | NA | NA | 96.7 |
Negative Predictive Value of tachograms for the identification of AF by ambulatory ECG.
| percentage of tachograms | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|
| TACHOGRAM NEGATIVE PREDICTIVE VALUE [AFBF] | NA | NA | 97.1 |
Day-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific day of the week.
| percent of iterations achieving success | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|
| DAY-SPECIFIC AF BURDEN ESTIMATE [AFBF] | NA | NA | 62.5 |
Four-hour segment-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific four-hour segment of a day
| percent of iterations achieving success | COHORT 3 | COHORT 4 | Overall |
|---|---|---|---|
| FOUR-HOUR SEGMENT SPECIFIC AF BURDEN ESTIMATE [AFBF] | NA | NA | 99.95 |
Collected over 3.5 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| COHORT 1 | 0/78 (0%) | 0/78 (0%) | 3/78 (3.8%) |
| COHORT 2 | 0/82 (0%) | 0/82 (0%) | 11/82 (13.4%) |
| COHORT 3 | 0/366 (0%) | 7/366 (1.9%) | 46/366 (12.6%) |
| COHORT 4 | 0/47 (0%) | 0/47 (0%) | 3/47 (6.4%) |
| Event | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 |
|---|---|---|---|---|
| Arteriosclerosis coronary arteryCardiac disorders | 0/78 | 0/82 | 1/366 | 0/47 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/78 | 0/82 | 1/366 | 0/47 |
| COVID-19 pneumoniaInfections and infestations | 0/78 | 0/82 | 1/366 | 0/47 |
| SepsisInfections and infestations | 0/78 | 0/82 | 1/366 | 0/47 |
| Metabolic encephalopathyNervous system disorders | 0/78 | 0/82 | 1/366 | 0/47 |
| Angina pectorisCardiac disorders | 0/78 | 0/82 | 1/366 | 0/47 |
| Dementia/AstheniaNervous system disorders | 0/78 | 0/82 | 1/366 | 0/47 |
| Sinus node dysfunctionCardiac disorders | 0/78 | 0/82 | 1/366 | 0/47 |
| Event | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 |
|---|---|---|---|---|
| Dermatitis ContactSkin and subcutaneous tissue disorders | 3/78 | 11/82 | 46/366 | 3/47 |
| Age, Categorical(Participants) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 60 | 45 | 144 | 14 | 263 |
| >=65 years | 18 | 37 | 222 | 33 | 310 |
| Age, Continuous(years) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Total |
|---|---|---|---|---|---|
| Mean | 49.2 ± 16.68 | 61.2 ± 15.07 | 65.4 ± 11.79 | 70.0 ± 8.85 | 63.0 ± 14.09 |
| Sex: Female, Male(Participants) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Total |
|---|---|---|---|---|---|
| Female | 40 | 53 | 180 | 14 | 287 |
| Male | 38 | 29 | 186 | 33 | 286 |
| Ethnicity (NIH/OMB)(Participants) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 1 | 17 | 2 | 38 |
| Not Hispanic or Latino | 60 | 81 | 349 | 45 | 535 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 | 1 | 5 |
| Asian | 0 | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 19 | 7 | 27 | 4 | 57 |
| White | 57 | 74 | 330 | 41 | 502 |
| More than one race | 0 | 0 | 5 | 0 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Total |
|---|---|---|---|---|---|
| United States | 78 | 82 | 366 | 47 | 573 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Apr 2021, 5 months.
Results were first posted in Aug 2022, 1 year 4 months after primary completion.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 5 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Apple Inc.